InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,308.13
(
1.17%
)
US TECH 100
18,111.60
(
1.54%
)
Dow Jones
39,908.07
(
0.88%
)
Brent Oil
82.73
(
0.22%
)
Bitcoin
66,052.15
(
7.32%
)
Post# of 251826
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: jellybean post# 161059

Monday, 05/13/2013 4:58:45 PM

Monday, May 13, 2013 4:58:45 PM

Post# of 251826
I see that MYGN already published 3 peer-reviewed papers on Prolaris test with the Lancet oncology being the first in 2011. Full data from the Duke university study I linked to in #msg-87805550 should be published soon (has been accepted). As for GHDX, didn't see any peer-reviewed paper just the PR and Abstract no 2131 at AUA 2013 with no detailed data. So, at this point it is impossible to know which test is a better outcome predictor for prostate cancer patients.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up